Mucosal effects of tenofovir 1% gel
Tenofovir gel is being evaluated for vaginal and rectal pre-exposure prophylaxis against HIV transmission. Because this is a new prevention strategy, we broadly assessed its effects on the mucosa. In MTN-007, a phase-1, randomized, double-blinded rectal microbicide trial, we used systems genomics/pr...
Main Authors: | Florian Hladik, Adam Burgener, Lamar Ballweber, Raphael Gottardo, Lucia Vojtech, Slim Fourati, James Y Dai, Mark J Cameron, Johanna Strobl, Sean M Hughes, Craig Hoesley, Philip Andrew, Sherri Johnson, Jeanna Piper, David R Friend, T Blake Ball, Ross D Cranston, Kenneth H Mayer, M Juliana McElrath, Ian McGowan |
---|---|
Format: | Article |
Language: | English |
Published: |
eLife Sciences Publications Ltd
2015-02-01
|
Series: | eLife |
Subjects: | |
Online Access: | https://elifesciences.org/articles/04525 |
Similar Items
-
Evaluation of Rapidly Disintegrating Vaginal Tablets of Tenofovir, Emtricitabine and Their Combination for HIV-1 Prevention
by: Meredith R. Clark, et al.
Published: (2014-12-01) -
Phase 1 randomized pharmacokinetic and safety study of a 90‐day tenofovir vaginal ring in the United States
by: Albert Y. Liu, et al.
Published: (2024-03-01) -
Release of Tenofovir from Carrageenan-Based Vaginal Suppositories
by: Toral Zaveri, et al.
Published: (2014-07-01) -
Lipid Vesicles Loaded with an HIV-1 Fusion Inhibitor Peptide as a Potential Microbicide
by: Elena Sánchez-López, et al.
Published: (2020-05-01) -
A latent trajectory analysis of young sexual and gender minorities’ adherence to three rectal microbicide placebo formulations (MTN-035; a randomized crossover trial)
by: Seul Ki Choi, et al.
Published: (2023-12-01)